112 VIEWPOINT Startups like Biolevate, Causaly and Dawn Health are developing AI-powered tools to help advance innovation across the life sciences value chain SALLY ANN FRANK: MICROSOFT From discovery to delivery Innovation is rarely a single breakthrough moment in life sciences. It is a chain of progress that begins with scientific discovery, moves through development and regulatory preparation, and only creates real impact when a therapy, service, or digital tool reaches the people who need it. Each link in the chain is under pressure. Research teams must sift through overwhelming volumes of biomedical evidence. Commercial and regulatory teams must translate complex science into rigorous, decision-ready documentation. And, once a product reaches the market, pharmaceutical companies must still engage patients in personal, compliant and scalable ways. Together Causaly, Biolevate and Dawn Health tell a compelling story about how AI and cloud technologies can help accelerate the path from idea to impact. These companies address different stages of the same broader problem: how to move faster without compromising scientific rigour, regulatory integrity or patient trust. Causaly focuses on the earliest stages of research and development. Biolevate helps life sciences organisations operationalise knowledge and documentation across development and commercialisation. Dawn Health extends digital innovation into the patient experience, helping pharmaceutical companies support people beyond the clinic. Together, they reflect a wider shift towards connected, AI-enabled ecosystems rather than isolated point solutions. Causaly represents the front end of this journey: the search for insight that can lead to better therapies. The company has built an AI platform for life sciences research and development to help scientists move from questions to evidence-backed answers more quickly. In a field where researchers need to review enormous bodies of literature, analyse biological relationships and compare competitive pipelines, speed alone is not enough. Instead, what matters is transparent, science-grade reasoning. Causaly’s platform is purpose-built to address this challenge, combining broad biomedical knowledge with tools that help teams retrieve, analyse and synthesise information to support confident decision-making. The solution saves scientists substantial time in identifying and validating targets, while also reducing the risk of missing key insights hidden across fragmented sources. Biolevate helps life sciences organisations communicate, validate and operationalise their work as it advances toward the market. This is a less visible stage of the value chain, but no less critical. Life sciences companies generate enormous amounts of documentation across clinical, regulatory, quality and market-facing activities, and “ Organisations will look for ways to connect insight generation with operational execution and patient experience”
RkJQdWJsaXNoZXIy NzQ1NTk=